Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Immune Checkpoint Blockade: The New Big Idea In Cancer

Executive Summary

Biologics that target immune checkpoints co-opted by cancer resistance have been significantly de-risked by the success of Bristol’s immunotherapy Yervoy and the progress of its Phase III candidate nivolumab. With six companies now testing candidates in the clinic, the class promises to have a big impact on oncology over the next several years, with the possibility of a next-generation approval by 2015.

You may also be interested in...



Opdivo Lung Cancer Approval Exceeds Rosiest Expectations

Even given huge optimism to date for immunotherapy checkpoint inhibitors, the rapid approval of Bristol’s PD-1 inhibitor nivolumab in squamous type lung cancer is a welcome surprise and bodes well for the class in the future.

Reading The Tea Leaves For PD-1 Family In New Hematology Data

Nivolumab investigator, ASH presidential symposium speaker and translational biologist Margaret Shipp explains in an interview why PD-1 blockade might be better in Hodgkin lymphoma than PD-L1 inhibition, and contemplates the future in other blood diseases.

Japan Earnings Highlights: New Products Win The Day For Top Pharma

PharmAsia News brings highlights from Japan’s week of earnings presentations.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS055301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel